Drug-eluting stents versus bare metal stents.
作者信息
Conti C Richard
出版信息
Clin Cardiol. 2003 Nov;26(11):493-4. doi: 10.1002/clc.4960261102.
Abstract
摘要
相似文献
1
Drug-eluting stents versus bare metal stents.
Clin Cardiol. 2003 Nov;26(11):493-4. doi: 10.1002/clc.4960261102.
2
Can we afford to eliminate restenosis? Can we afford not to?
J Am Coll Cardiol. 2004 Feb 18;43(4):513-8. doi: 10.1016/j.jacc.2003.11.020.
3
Are drug-eluting stents cost-effective? It depends on whom you ask.
Circulation. 2006 Oct 17;114(16):1736-43; discussion 1744. doi: 10.1161/CIRCULATIONAHA.105.546010.
4
5
Drug-eluting stents: the price is not right.
Circulation. 2006 Oct 17;114(16):1745-54; discussion 1754. doi: 10.1161/CIRCULATIONAHA.106.646190.
6
Drug-eluting stents substantially lower rate of restenosis.
Rep Med Guidel Outcomes Res. 2003 Oct 17;14(20):7-9.
7
The costs and quality-of-life outcomes of drug-eluting coronary stents: a systematic review.
J Interv Cardiol. 2007 Feb;20(1):1-9. doi: 10.1111/j.1540-8183.2007.00214.x.
8
Drug-eluting versus bare-metal coronary stents: where are we now?
J Comp Eff Res. 2012 Nov;1(6):501-8. doi: 10.2217/cer.12.64.
9
Predicting the restenosis benefit of drug-eluting versus bare metal stents in percutaneous coronary intervention.
Circulation. 2011 Oct 4;124(14):1557-64. doi: 10.1161/CIRCULATIONAHA.111.045229. Epub 2011 Sep 6.
10
Drug eluting stents: maximising benefit and minimising cost.
Heart. 2003 Feb;89(2):127-31. doi: 10.1136/heart.89.2.127.
引用本文的文献
1
Physician factors as an indicator of technological device adoption.
J Med Syst. 2006 Jun;30(3):177-86. doi: 10.1007/s10916-005-8066-2.
Zotero 插件